Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
35 hedge funds and large institutions have $25.4M invested in Viracta Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 5 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
5% less funds holding
Funds holding: 37 → 35 (-2)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
31% less capital invested
Capital invested by funds: $36.5M → $25.4M (-$11.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$636K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$227K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$125K |
| 4 |
TI
Telemetry Investments
New York
|
+$85.7K |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.1M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.03M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$190K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$44.3K |
| 5 |
Renaissance Technologies
New York
|
-$37.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EAM
26
Eventide Asset Management
Boston,
Massachusetts
| $25K | +$30.5K | +374 | New |
|
27
JP Morgan Chase
New York
| $22K | +$27.4K | +335 | New |
|
|
VF
28
Virtu Financial
New York
| $20K | +$23.5K | +288 | New |
|
29
UBS Group
Zurich,
Switzerland
| $17K | +$15.9K | +195 | +375% |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| $16K | +$19.7K | +241 | New |
|
31
Bank of America
Charlotte,
North Carolina
| $9K | – | – | – |
|
|
DCM
32
Driehaus Capital Management
Chicago,
Illinois
| – | -$1.1M | -11,598 | Closed |
|
|
OM
33
Opaleye Management
Boston,
Massachusetts
| – | -$1.03M | -10,857 | Closed |
|
34
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$1K | -8 | Closed |
|
35
Group One Trading
Chicago,
Illinois
| – | -$327 | -4 | Closed |
|
VIRX Hedge Fund Activity: Q3 2017 in Review
35 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q3 2017, worth a combined $25.4M — down 31% from $36.5M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of VIRX and 4 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 8 added.
The largest buyer was BVF Inc, adding an estimated $636K. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $1.1M sold.
- 35 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q3 2017, down from 37 in Q2 2017.
- Funds reported $25.4M of Viracta Therapeutics, Inc. Common Stock stock for Q3 2017, down 31% quarter-over-quarter.
- 4 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q3 2017 and 5 closed out, a net change of -1 holder.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q3 2017 was BVF Inc, an estimated $636K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q3 2017 was Driehaus Capital Management, an estimated $1.1M sold.
Based on aggregated 13F filings for Q3 2017.